This article was originally published in Pharmaceutical Approvals Monthly
Enrollment begins for a three-year study in more than 1,000 patients to test safety and efficacy of celecoxib in reducing the occurrence of new, sporadic adenomatous polyps in the colon and rectum in patients with at least one previously removed polyp. The multicenter, randomized, double-blind, placebo-controlled trial will test patients with a history of, but not a familial disposition toward, adenomatous polyps, which "are a precursor to more than 95 percent of all colorectal cancers," according to the companies. In December, the COX-2 inhibitor was approved for treatment of patients with familial adenomatous polyposis. Celebrex also is indicated for use in osteoarthritis and rheumatoid arthritis
You may also be interested in...
Industry access to real world data for regulatory and market access purposes in Asia Pacific compares poorly with the US.
In an exclusive interview with Generics Bulletin, Inflexion’s Ben Long reveals his ambitions for newly-acquired UK-based liquids generics specialist Rosemont Pharmaceuticals, including to drive investment in R&D and expand the company’s international footprint.
“With so little publicly available information on the safety of CBD we anticipate that directly relevant studies will be needed,” explains the UK Food Standards Agency, in response to confusion within the country's CBD industry.